Companion Diagnostics Market, By Technology Type (Real Time-Polymerase Chain Reactions (PCR), Gene Sequencing, Fluorescence in situ Hybridization, and Others) By Application (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Diseases an

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	160 Pages	Coherent Market Insights	March, 2025	CMI20004442

Best Price Guarantee
Price	from $4,500
Length	160 Pages
Publisher	Coherent Market Insights
Published Date	March, 2025
SKU	CMI20004442

Companion diagnostics are medical devices that are used to detect specific biomarkers or genes in patients that help determine which patients are most suitable candidates for a particular therapy. These diagnostics play an important role in personalized healthcare by helping physicians select appropriate targeted treatment options for cancer and other diseases. Companion diagnostics tests evaluate the expression of biomarkers, such as proteins, genes or chromosomes that plays a role in a patient’s response to a specific drug. By analyzing the expression levels of such biomarkers, these tests help to identify whether a particular drug would be safe and effective for a specific patient or set of patients with a given disease. This enables better therapeutic outcomes by ensuring only suitable patients receive specialized treatments.

Market Dynamics:

Global companion diagnostics market is driven by rising demand for personalized medicine, growth in molecular diagnostics, increasing approvals of new targeted therapies & companion diagnostics, technological advancements, and growing incidence and prevalence of cancer, and other chronic diseases. However, the market growth can be restricted by high pricing pressure and regulatory hassles that are involved in developing and commercializing these molecular diagnostic tests. Key opportunities in this market include developing biomarkers and companion diagnostics for immunotherapies, expanding applications in non-oncology diseases, precision medicine collaborations between In vitro diagnostics (IVD) companies and drug makers, growing focus on companion diagnostic development in emerging markets, and adoption of advanced technologies like Next-generation sequencing (NGS) for biomarker detection.

Key features of the study:

This report provides in-depth analysis of the global companion diagnostics market, and provides market size (US$ Bn)and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global companion diagnostics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V, Abbott Laboratories, Inc., Almac Group, Danaher Corporation, Illumina, Inc., bioMérieux SA, Myriad Genetics, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Abnova Corporation, Guardant Health, Inc., Icon Plc., and Biogenex Laboratories, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global companion diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global companion diagnostics market

Detailed Segmentation:

Global Companion Diagnostics Market, By Technology Type
Real Time-Polymerase Chain Reactions (PCR
Gene Sequencing
Fluorescence in situ Hybridization
Others
Global Companion Diagnostics Market, By Application
Oncology
Cardiovascular Diseases
Infectious Diseases
Neurological Diseases
Others
Global Companion Diagnostics Market, By End User
Hospitals
Research Laboratories
Biopharmaceutical companies
Others
Global Companion Diagnostics Market, By Region
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Company Profiles
F.Hoffmann-La Roche AG
Agilent Technologies, Inc.
QIAGEN N.V
Abbott Laboratories, Inc.
Almac Group
Danaher Corporation
Illumina, Inc.
bioMérieux SA
Myriad Genetics, Inc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Abnova Corporation
Guardant Health, Inc.
Icon Plc.
Biogenex Laboratories, Inc.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Technology Type; Market Snippet, By Application; Market Snippet, By End User; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Increasing number of cancer patients; Complexity of Integration; Emerging markets; Key Highlights; Regulatory Scenario; Recent Trends; Product Launches/Approvals; PEST Analysis; PORTER’s Analysis; Mergers, Acquisitions and Collaborations
4. Global Companion Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic: COVID-19 Epidemiology; Supply Side and Demand Side Analysis; Economic Impact
5. Global Companion Diagnostics Market, By Technology Type, 2020-2032, (US$ Bn): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segment Trends; Real Time-Polymerase Chain Reactions (PCR); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Gene Sequencing; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Fluorescence in situ Hybridization; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Companion Diagnostics Market, By Application, 2020-2032, (US$ Bn): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segment Trends; Oncology; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Cardiovascular Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Infectious Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Neurological Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Companion Diagnostics Market, By End User, 2020-2032, (US$ Bn): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segment Trends; Hospitals; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Research Laboratories; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Biopharmaceutical companies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Companion Diagnostics Market, By Region, 2020-2032, (US$ Bn): Introduction; Market Share Analysis, By Region, 2025 and 2032 (%); Y-o-Y Growth Analysis, For Region, 2021 –2032; Country Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn); U.S.; Canada; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn); Germany; U.K.; Spain; France; Italy; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn); China; India; Japan; Australia; South Korea; ASEAN; Rest of Asia Pacific; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn); Brazil; Argentina; Mexico; Rest of Latin America; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn); GCC Countries; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn); South Africa; North Africa; Central Africa
9. Competitive Landscape: Company Profiles; F.Hoffmann-La Roche AG; Company Highlights; Product Portfolio; Key Developments; Financial Performance; Strategies; Agilent Technologies, Inc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; QIAGEN N.V; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Abbott Laboratories, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Almac Group; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Danaher Corporation; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Illumina, Inc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; bioMérieux SA; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Myriad Genetics, Inc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Sysmex Corporation; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Thermo Fisher Scientific Inc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Abnova Corporation; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Guardant Health, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Icon Plc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Biogenex Laboratories, Inc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Analysts’ Views
10. Section: References; Research Methodology; About us; *Browse 35 market data tables and 35 figures on “Global Companion Diagnostics Market” - Global forecast to 2032